A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin LA 11.25 mg) in Patients With Advanced Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2014
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms PAMIS
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004139).
- 29 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.